Dexcom Receives FDA Approval For G6 Pro CGM

Dexcom Receives FDA Approval For G6 Pro CGM
-Daniel Pereira
Dexcom announced on Tuesday that the U.S. Food and Drug Administration has granted its approval for the Dexcom G6 Pro CGM, a monitoring device designed specifically for use by healthcare professionals within the context of a clinic or hospital. Professional or clinical CGMs are often employed by healthcare professionals who want to “test out” the technology on patients who may be unsure about committing to the technology.
The single use, professional CGM records real-time glucose data over a 10-day period, and is the only device of its specific type currently on the market. One of its features is the ability to be used in either “blinded” or “unblinded” mode – either hiding its recording data from the patient to which its been prescribed or allowing them to view that data during the 10-day period. Clinicians can choose which mode they want to employ when setting the device up for their patients.
The G6 Pro is otherwise relatively similar to the consumer-facing G6 sensor model, with one-touch insertion, factory calibration, and automatic readings every five minutes.
“This new professional system will serve as a simple way to obtain data from CGM naïve patients who need glucose insight, but don’t need or want to be monitored around the clock,” Davida Kruger, MSN, APN-BC, BC-ADM, a diabetes specialist at the Henry Ford Health System in Detroit wrote in a Dexcom press release. “It will give all my patients a chance to try the Dexcom G6 Pro under a healthcare provider’s supervision before they commit to a personal system.”
The company expects that it will be able to ship the Dexcom G6 Pro to its customers early in 2020.
To read the full press release, click here. To read more about Dexcom’s plans for future device development, click here
Note: The lead image is technically of the Dexcom G6 sensor, not the Dexcom G6 Pro. 
Join T1D Exchange Glu for more type 1 diabetes news.

Sign in or Register to view comments.